Bausch Health Companies Inc. (BHC)

NYSE - NYSE Delayed Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

30.03-0.27 (-0.89%)

At close: 4:00PM EDT

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	30.30
Open	30.39
Bid	30.02 x 900
Ask	30.10 x 1200
Day's Range	29.89 - 30.50
52 Week Range	14.86 - 34.80
Volume	1,801,281
Avg. Volume	4,798,357

Market Cap	10.703B
Beta (5Y Monthly)	1.73
PE Ratio (TTM)	N/A
EPS (TTM)	-1.58
Earnings Date	May 04, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	Nov 10, 2010
1y Target Est	35.06

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

CNW Group
Bausch Health Announces VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is Now Approved In Brazil
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, its leading global eye health business, and Nicox (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária).
CNW Group
New Report Reveals That More Than One-Third Of IBS Patients Surveyed State It Has Been More Challenging To Manage Their Symptoms During The COVID-19 Pandemic
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today released a report of survey results that offers perspectives from U.S. adults living with irritable bowel syndrome (IBS) during the COVID-19 pandemic. Entitled Patient Perspectives: Living with IBS in a Pandemic, the report provides insights about the symptoms and behaviors of IBS patients over the past year (March 2020 – March 2021). Most notably, more than one-third (37%) of those surveyed acknowledge that the COVID-19 pandemic has made it more challenging to manage their IBS symptoms. The report, which was developed based on a survey conducted by The Fairleigh Dickinson University Poll, also finds concerns about post-pandemic life and insights about the way patients are communicating with their health care providers.
- Urgent need for blood donations
  41 Action News
- 2021 Global Report on B2B E-Commerce - Challenges and Opportunities Caused by Digital Acceleration - ResearchAndMarkets.com
  Business Wire
Zacks
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery
3 Generic Drug Stocks to Watch Amid COVID-Related Recovery